Danish drug giant found to have failed to accurately report spending even after admitting to errors
The pharmaceutical watchdog has reprimanded Wegovy maker Novo Nordisk for failing to correctly disclose dozens of payments to the UK health sector as it sought to boost sales of its slimming drugs.
The Danish drug giant – Europe’s most valuable listed company – systematically misreported, under-reported or did not disclose funding given over seven years to pharmacy firms, obesity charities, training providers, professional bodies and patient groups.
About Author
More Stories
Microsoft unveils chip it says could bring quantum computing within years
I became absorbed in strangers’ fertility journeys online
Virologist Wendy Barclay: ‘Wild avian viruses are mixing up their genetics all the time. It’s like viral sex on steroids’